下三分之一阴道受累的宫颈癌患者结局评估:单机构经验
本研究回顾性分析2010至2016年在本机构接受放(化)疗的118例FIGO 2009分期IIIA及IIIB期、下三分之一阴道受累的浸润性宫颈癌患者,中位随访30个月,3年无病生存率与总生存率分别为61.5%和69.8%;单因素分析显示IIIA期患者3年无病生存率与总生存率均显著优于IIIB期患者。
要点
- IIIA期患者3年无病生存率71% vs IIIB期56%(P=0.02),3年总生存率76% vs 66%(P=0.01)。
- 同步化疗与无持续病灶是多因素分析中的独立生存预测因素。
- 老年、未接受同步化疗及近距离放疗时存在残留病灶与较差结局相关。
核心结论
- 下三分之一阴道受累的FIGO IIIA期宫颈癌患者结局优于IIIB期患者。
- 老年、未接受同步化疗及近距离放疗时存在残留病灶与较差结局相关。
研究设计与样本
- 回顾性分析2010至2016年在本机构接受放(化)疗的118例组织学证实的浸润性宫颈癌患者,临床FIGO-2009分期IIIA和IIIB期,均伴下三分之一阴道受累。
主要发现
- 患者中位年龄56.5岁(范围33-77岁),45例为FIGO IIIA期,73例为IIIB期,以鳞状细胞组织学为主。
- 中位随访30个月,12例(10.1%)出现局部阴道复发,4例(3.3%)出现局部区域复发,27例(23%)出现远处转移,2例出现局部区域及远处复发。
- 3年无病生存率和总生存率分别为61.5%和69.8%。
- 单因素分析显示IIIA期患者3年无病生存率71% vs IIIB期56%(P=0.02),3年总生存率76% vs 66%(P=0.01),IIIA期均显著优于IIIB期。
- 多因素分析显示同步化疗和无持续病灶是生存的独立预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE(S): The objective of this study was to evaluate the clinical outcomes and prognostic factors affecting survival of cervical cancer patients presenting with lower third vaginal involvement. MATERIALS/METHODS: The patients with histologically proven invasive cervical cancer with clinical FIGO-2009 stage IIIA and IIIB with lower one-third vaginal involvement, treated with radio (chemo) therapy between 2010 and 2016 at our institution were retrospectively analyzed. RESULTS: There were 118 cervical cancer patients with lower third vaginal involvement with median age of 56.5 years (Range: 33-77 years). Forty-five patients were of FIGO stage IIIA, 73 patients staged as stage IIIB at diagnosis with predominant squamous histology. At a median follow up of 30 months, 12 patients (10.1%) developed local vaginal recurrences and 4 patients (3.3%) had developed loco regional recurrences, 27 patients (23%) developed distant and 2 patients developed loco-regional and distant relapses. The 3- year DFS and OS rates were 61.5% and 69.8% respectively. The 3-year DFS and OS of patients with IIIA was significantly better than IIIB patients (71% vs 56%, p: 0.02 and 76% vs 66%, p: 0.01 respectively) on univariate analysis. Concurrent chemotherapy and absence of persistent disease emerged as independent predictors of survival on multi-variate analysis. CONCLUSION: The outcome of patients with FIGO IIIA is better than IIIB with lower vaginal involvement. Elderly patients, patients not receiving concomitant chemotherapy and presence of residual disease at BT are associated with poorer outcomes.
引用
- Gurram L, Patil R, Chopra S, et al. Evaluation of outcomes in patients of cervical Cancer with lower one third vaginal involvement: A single institutional experience. Gynecol Oncol. 2020. PMID: 32829963. doi:10.1016/j.ygyno.2020.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。